Stereotaxis (STXS) AI Stock Analysis

• Market Cap: $200.36M
• Dividend Yield: N/A
• Average Volume (3M): 541.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 1.50%
• EPS Growth: -20.00%
• Country: US
• Employees: 139
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 90,250,850
• 10 Day Avg. Volume: 992,442
• 30 Day Avg. Volume: 541,089
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 5.63
• Enterprise Value/Gross Profit: 10.55
• Enterprise Value/Ebitda: -6.20
• 1Y Price Target: $4.50
• Price Target Upside: 102.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 64 Neutral
• Price Target: $2.50 ▲(12.61%Upside)

The overall score of 64 reflects the company's strengths in revenue growth and strategic financial moves such as the stock offering, bolstered by neutral technical indicators. However, ongoing financial challenges and valuation concerns moderate the score.

Positive Factors

Product Performance

Initial peer-reviewed results for Stereotaxis’ MAGiC catheter show 94% acute efficacy and strong safety across a broad range of arrhythmias.

Regulatory Progress

The publication supports the company's ongoing commercial rollout of the MAGiC catheter in Europe and should support the US regulatory filing.

Revenue Growth

STXS posted 1Q revenue of $7.5M, beating the Street's $6.9M estimate by a comfortable margin.

Negative Factors

Market Competition

The need for continuous innovation and enhancement may pressure the company to invest heavily in R&D to maintain its competitive edge.

Regulatory Delays

Potential delays in FDA approval for the MAGiC catheter in the U.S. could impact growth expectations.

Stereotaxis Business Overview & Revenue Model

Company Description

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

How the Company Makes Money

Stereotaxis generates revenue primarily through the sale of its robotic systems and related products. This includes the initial sale of the robotic navigation systems, as well as recurring revenue from the sale of disposable components and service agreements. The company also earns income through partnerships with hospitals and medical centers, providing them with the necessary technology and support for advanced cardiac procedures. Additionally, Stereotaxis may earn from training and support services offered to healthcare providers to ensure effective use of their systems.

Stereotaxis Financial Statement Overview

Summary

Stereotaxis has strong gross margins but struggles with profitability due to high operational costs leading to negative net income. The balance sheet shows balanced leverage but limited equity. Cash flow challenges indicate a need for improved cash management.

Income Statement

Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.

Balance Sheet

The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.

Cash Flow

Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.92M	26.77M	28.15M	35.02M	26.63M
Gross Profit	14.59M	14.86M	18.47M	23.23M	18.97M
EBITDA	-23.77M	-21.24M	-18.35M	-12.78M	-6.59M
Net Income	-24.05M	-20.71M	-18.29M	-8.44M	-6.65M
Balance Sheet
Total Assets	46.72M	41.91M	53.41M	60.98M	55.46M
Cash, Cash Equivalents and Short-Term Investments	12.22M	19.82M	28.43M	38.74M	43.94M
Total Debt	6.01M	5.49M	5.86M	6.11M	4.45M
Total Liabilities	35.29M	19.99M	21.48M	21.56M	15.23M
Stockholders Equity	11.43M	21.92M	31.93M	39.42M	40.23M
Cash Flow
Free Cash Flow	-8.53M	-9.51M	-10.79M	-4.34M	-3.58M
Operating Cash Flow	-8.50M	-9.14M	-8.41M	-2.95M	-3.51M
Investing Cash Flow	74.00K	19.77M	-22.09M	-1.40M	-70.90K
Financing Cash Flow	297.00K	81.00K	220.00K	547.41K	17.34M

Stereotaxis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.22
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Negative. The current price of 2.22 is below the 20-day moving average (MA) of 2.29, below the 50-day MA of 2.22, and above the 200-day MA of 2.11, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 47.07 is Neutral, neither overbought nor oversold. The STOCH value of 25.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXS.

Stereotaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HOLX	74 Outperform	$14.94B	27.86	11.38%	―	1.28%	-17.73%
ATR	71 Outperform	$9.33B	24.38	15.36%	1.27%	1.51%	21.70%
ATRC	68 Neutral	$1.71B	―	-7.85%	―	16.28%	10.63%
MMSI	66 Neutral	$5.02B	43.07	8.60%	―	10.14%	0.04%
STXS	64 Neutral	$200.36M	―	-179.82%	―	1.50%	-20.00%
STAA	56 Neutral	$879.58M	55.81	-19.14%	―	-14.44%	-557.38%
Sector *	51 Neutral	$7.38B	0.34	-69.01%	2.37%	16.35%	0.39%

Stereotaxis Corporate Events

Stereotaxis Announces $12.5M Stock Offering

On July 17, 2025, Stereotaxis announced a $12.5 million registered direct offering of common stock, priced at $2.00 per share, led by a strategic industry partner and select institutional investors. The company plans to use the proceeds to accelerate product commercialization, research and development, and other corporate purposes. The initial closing is expected on July 18, 2025, with proceeds of $8.5 million, and a second closing on November 25, 2025, for $4.0 million. This funding is expected to strengthen Stereotaxis’ balance sheet and support its innovation strategy.

The most recent analyst rating on (STXS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.

Stereotaxis Holds 2025 Annual Shareholders Meeting

On May 15, 2025, Stereotaxis held its Annual Meeting of Shareholders, where a 59% quorum was achieved with 63,792,419 shares represented. During the meeting, shareholders elected two Class III directors to serve until the 2028 Annual Meeting and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025. The election of directors was determined by a plurality of votes, and the proposal to ratify the accounting firm was passed by a majority of the outstanding shares.

The most recent analyst rating on (STXS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.